(PharmaNewsWire.Com, November 29, 2019 ) This growth can be attributed to factors such as advancements in transfection technology, global alliances among leading research institutes to trigger drug discovery, increase in R&D spending and research activities by pharmaceutical and biotechnology companies, increase in demand for synthetic genes, and rising incidence of cancer.
Moreover, development of large scale transfections, rising demand of protein therapeutics, and emerging markets across India and China are likely to create opportunities for players operating in the market.
Based on product, the transfection reagents and equipment market is categorized into reagents and instruments. In 2016, the reagents segment is estimated to account for the largest share of the market. However, the instruments market is likely to grow at the highest CAGR during the forecast period.
Please share your specific interest to serve you better | Download PDF Brochure@
On the basis of method, this market is segmented into biochemical, physical, and viral methods. In 2016, the biochemical method segment is expected to account for the largest share of the market, while the viral method segment is expected to grow at the highest CAGR during the forecast period. The biochemical method segment is further classified into calcium phosphate, lipofection DEAE-dextran, and dendrimer. Whereas, the physical method segment is further divided into electroporation, nucleofection, and others (gengun, sonoporation, magnetofection, and optoinjection).
Based on application, the market is segmented into biomedical research, protein production, and therapeutic delivery. In 2016, the biomedical research segment is estimated to account for the largest share of the market.
Based on end user, the market is segmented into academic & research institutes and pharmaceutical & biotechnologies companies. In 2016, the academic & research institutes segment is excepted to account for the largest share of the market. However, the pharmaceutical & biotechnologies segment is projected to grow at the highest CAGR during the forecast period.
On the basis of region, the global transfection reagents and equipment market is divided into North America, Europe, Asia-Pacific, and Rest of the World (RoW). In 2016, North America is poised to account for the largest share of the market, followed by Europe and Asia-Pacific. However, the Asia-Pacific market is slated to grow at the highest CAGR during the forecast period and serve as a major revenue pocket for companies offering transfection reagents and equipment.
Over the years, the transfection reagents and equipment market has witnessed various technological advancements to meet the needs of researchers and biotechnology & pharmaceutical companies. These advancements have led to the development of high throughput large scale transfection instruments and reagents with greater efficiency. Advanced technologies result in efficient quantitative and qualitative transfection in varied types of cells, including the hard-to-transfect cell lines.
Please share your specific interest to serve you better | Request Sample Pages@
The prominent players in the global transfection reagents and equipment market include Thermo Fisher Scientific Inc. (U.S.), Promega Corporation (U.S.), Hoffmann-La Roche Ltd. (Switzerland), and QIAGEN N.V. (Netherlands). These companies hold a dominant position in the transfection reagent and equipment market mainly due to their well-established presence in the field of genomics, presence in over 50 countries, high R&D investments, and strong sales and distribution force. Other players in the market include Polyplus-transfection SA (France), Bio-Rad Laboratories (U.S.), Lonza Group (Switzerland), Sigma-Aldrich Corporation (U.S.), Mirus Bio LLC (U.S.), and MaxCyte Inc. (U.S.).
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: